Opthea (OPT) – Press Releases
-
Opthea to Present at the OIS Retina Innovation Summit at ARVO
-
Optiva and GDi Announce Strategic Partnership to Deliver Integrated BSS and OSS Solutions
-
Opthea Appoints John Han, PharmD, as VP Medical Affairs
-
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
-
Opthea Appoints Sujal Shah to the Board of Directors
-
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
-
Optiva Inc. Reports Fourth Quarter 2023 Financial Results
-
Opthea to Participate in the Leerink Partners Global Biopharma Conference
-
Opthea Reports Half-Year Financial Results and Business Updates
-
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
-
Optiva Accelerates Competitive Edge With Generative AI-Enabled Real-Time BSS
-
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
-
Opthea Strengthens Team with Key Clinical and Regulatory Hires
-
BT Group Selects Optiva for Next-Generation Application Server Upgrade to Build and Deploy Innovative New Services
-
Optiva Reports Preliminary Fourth Quarter and Full Year 2023 Revenue, and Provides Growth Outlook for 2024
-
Opthea Receives A$8.8 million R&D Tax Incentive
-
Humane Selects Optiva BSS for Launch of New Ai Pin
-
Optiva Inc. Reports Third Quarter 2023 Financial Results
-
REALLY Selects Optiva to Help Launch Its New Wireless Service and Decentralized Mobile Network
-
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
-
lifecell Ukraine and Optiva Named as a Winner of Excellence in Serving People and Planet in TM Forum’s 16th Annual Awards
-
Optiva MVNO Hubs Launched on Google Cloud, Offering BSS as a Service
-
Optiva Announces US$13.5 Million Secured Notes Financing
-
Telecom Operators Empowered by AI and Automation With Next-Generation Optiva Charging Engine
-
Optiva Inc. Reports Second Quarter 2023 Financial Results
-
Opthea To Present at the JMP Securities Life Sciences Conference
-
Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ
-
Opthea Receives A$8.7 million R&D Tax Incentive
-
Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference
-
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
-
Opthea To Present at SVB Leerink Global Biopharma Conference
-
Opthea To Present at Sequire Biotechnology Conference
-
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
-
Opthea to Present at the FLORetina 2022 Congress
-
Opthea to Present at Jefferies London Healthcare Conference
-
Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer
-
Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights
-
Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
-
Opthea Successfully Closes Well Supported US$90 Million Equity Financing
-
Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD
-
Loop Energy Appoints Kent Thexton as Director and Chair of the Board
-
Opthea To Present at Upcoming Investor Conferences
-
Opthea Presentation at The Retina World Congress 2022
-
Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022
-
Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting
-
Opthea strengthens its Board of Directors
-
Opthea To Present at Oppenheimer’s 32nd Annual Healthcare Conference
-
Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer
-
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022
-
Opthea To Present at SVB Leerink Global Healthcare Conference
Back to OPT Stock Lookup
